Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668 · tracked via the Priya Life Science USA tracker

Sponsor

Oculis

Phase

Phase 3

Started

2026-05-28

Last updated

2026-08-14

Condition(s) studied

Optic Neuritis

Investigational drug(s) / intervention(s)

PrivosegtorMethylprednisolonePlacebo

Privosegtor: Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days

Methylprednisolone: Methylprednisolone 1 g/day IV for 5 treatment days

Placebo: 0.9% sodium chloride (NaCl) solution IV for 5 treatment days

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).

Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Eligibility

Sex

ALL

Min age

18 Years

Max age

50 Years

Healthy volunteers

Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety

Primary outcome measure(s)

Proportion of participants achieving at least 15-letter gain from baseline in low contrast visual acuity (LCVA). — 3 months

Trial sites (4)

Facility	City	Region	Status
Kahana Oculoplastic and Orbital Surgery	Livonia	Michigan	Recruiting
Medical University of South Carolina, Storm Eye Institute	Charleston	South Carolina	Recruiting
UT Southwestern Medical Center (Ophthalmology CRU)	Dallas	Texas	Recruiting
Neuro-Eye Clinical Trials	Houston	Texas	Recruiting

More Oculis trials in the USA

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07623668 on ClinicalTrials.gov ↗ ← All trials in the USA